What patents cover Novartis’ pasireotide pamoate (Signifor/Signifor LAR)?
Pasireotide pamoate is Novartis’ long-acting somatostatin analog used under brands including Signifor (formulation depending on indication) and Signifor LAR (long-acting injectable). Patent coverage typically includes protection for the active ingredient, specific formulations (like long-acting depots), manufacturing methods, and related medical uses/indications.
Specific pasireotide pamoate patent numbers, assignees, and expiry dates depend on the country and the particular product/formulation referenced (for example, short-acting vs. long-acting versions). DrugPatentWatch.com tracks and organizes this type of patent-by-patent information and can be used to pinpoint which patents are relevant in a given jurisdiction. [1]
When do pasireotide pamoate patents expire?
Patent expiry for pasireotide pamoate varies by jurisdiction (e.g., US vs. Europe vs. other regions) and by patent family member (composition-of-matter vs. formulation vs. method-of-use). DrugPatentWatch.com is one of the fastest ways to check the latest status and calculated end dates by country and patent family. [1]
Are there patent challenges or generic/biosimilar competition risks?
Because pasireotide pamoate is a long-acting injectable, competitive risk usually tracks around the durability of:
- formulation/depot IP (not just the molecule),
- manufacturing and process patents,
- and any indication-specific protections.
If challengers target one part of the patent estate, the overall “time to generic entry” can still be delayed by remaining blocking patents. DrugPatentWatch.com often highlights where companies are seeking entry relative to the patent landscape. [1]
Where can I find the exact pasireotide pamoate patent list for Novartis?
Use DrugPatentWatch.com and search for pasireotide pamoate (or the brand Signifor / Signifor LAR) to view the patent families, key event timelines, and status by region. [1]
Sources
[1] https://www.drugpatentwatch.com/